Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TransMID vs Standard of Care in Recurrent GBM
NCT00088400Phase 3Completed
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Jul 2004
- Modality
- Immunotoxins
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in glioblastoma (GBM) comparing TransMID with Standard of Care (2 arms). Primary endpoint: Overall Survival. Started Jul 2004; status: completed.
02
Drugs
transmid
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT00088400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00088400.